Cumulative effects of hypertriglyceridemia in HIV-infected patients switching from NNRTIs to PI-based antiretroviral therapy.
Anti-HIV Agents
/ adverse effects
Anti-Retroviral Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
/ adverse effects
HIV Infections
/ complications
HIV Protease Inhibitors
/ therapeutic use
Humans
Hypertriglyceridemia
/ chemically induced
Lipids
/ therapeutic use
Reverse Transcriptase Inhibitors
/ adverse effects
Non-nucleoside reverse transcriptase inhibitors
highly active antiretroviral therapy
hypertriglyceridemia
protease inhibitors
Journal
Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410
Informations de publication
Date de publication:
31 03 2022
31 03 2022
Historique:
received:
05
02
2020
accepted:
14
07
2021
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
The objective of this study was to investigate changes in serum lipids among HIV-infected patients switching from non-nucleoside-reverse transcriptase inhibitors (NNRTI) to protease inhibitor (PI)-based highly active antiretroviral therapy (HAART), and to determine if changes of lipid profiles impacted the monocyte subsets recovery. Fifty-seven subjects who switched from NNRTIs to PI-based HAART (NNRTIs to PI group) and fifty-five subjects who initially started with PI-based HAART (initial PI group) were recruited. According to their baseline triglyceride (TG) levels, the NNRTIs to PI and initial PI groups were further divided into non-hypertriglyceridemia and hypertriglyceridemia subgroups, respectively. The effects of PI-based HAART on lipid profiles and monocyte subsets were analyzed. At 48 weeks, the TG changes in the NNRTIs to PI group was higher than that of the initial PI group. The increases of serum TG levels in the initial PI non-hypertriglyceridemia group was greater than that of the NNRTIs to PI non-hypertriglyceridemia group. For the hypertriglyceridemia group at baseline, significant increment in TG levels were observed in the NNRTIs to PI hypertriglyceridemia group. The percentages of circulating CD14highCD16+ and CD14lowCD16+ subsets were elevated in the two groups. At 48 weeks, the proportion of CD14highCD16+ monocytes declined gradually, and the proportion of CD14lowCD16+ monocytes decreased independently of the TG level. For non-hypertriglyceridemia individuals at baseline, PI-based regimens increased the TG level in the initial PI group. For the NNRTIs to PI hypertriglyceridemia group, PI-based regimens reinforced HAART-related hypertriglyceridemia.
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
HIV Protease Inhibitors
0
Lipids
0
Reverse Transcriptase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
528-536Informations de copyright
Copyright (c) 2022 Yu Zhang, Jiang Xiao, Wen Zhang, Ning Han, Di Yang, Wei Liu, Hui Zeng, Junyan Han, Hongxin Zhao.
Déclaration de conflit d'intérêts
No Conflict of Interest is declared